Literature DB >> 12127092

Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat.

J Prickaerts1, W C G van Staveren, A Sik, M Markerink-van Ittersum, U Niewöhner, F J van der Staay, A Blokland, J de Vente.   

Abstract

The present study investigated the effects of two cyclic GMP-specific phosphodiesterase enzyme type 5 inhibitors, sildenafil and vardenafil, on the memory performance in the object recognition task. Both compounds were given per orally (1, 3 and 10 mg/kg sildenafil; 0.1, 0.3, 1 and 3 mg/kg vardenafil) immediately after the exposure to two identical objects. The memory for the objects was tested 24 h later. Vehicle-treated rats spent equal times exploring a new and the familiar object demonstrating that they did not remember the familiar one. However, sildenafil improved the object discrimination performance of the rats with a high discrimination performance at a dose of 3 mg/kg. Rats treated with vardenafil also showed an improved object discrimination performance. Compared with sildenafil, vardenafil appeared to be even more potent in this respect since it already produced a high discrimination performance at a dose of 0.3 mg/kg. The effects of both compounds on cyclic GMP and cyclic AMP accumulation were studied in rat hippocampal slices incubated in vitro. Cyclic GMP levels were increased after incubation with the highest concentration of 100 microM vardenafil (together with 0.1 mM sodium nitroprusside), although no changes in cyclic GMP levels were detected after incubation with different concentrations of sildenafil. Both compounds had no effect on cyclic AMP levels. Additional cyclic GMP immunocytochemistry showed that incubation with vardenafil (in the presence of sodium nitroprusside) resulted in a concentration-dependent staining of cyclic GMP. Staining was predominantly found in neuronal fibres in the hippocampal CA2/CA3 region. It was already detected at a concentration of 0.1 microM vardenafil. Also positive fibres were detected after incubation with sildenafil but at a higher concentration of 10 microM. Taken together, these results suggest that inhibition of phosphodiesterase enzyme type 5 improves object recognition memory. This effect might be explained by increased levels of central cyclic GMP. Copyright 2002 IBRO

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127092     DOI: 10.1016/s0306-4522(02)00199-9

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  53 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.

Authors:  Andreas Friebe; Peter Sandner; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-10-20       Impact factor: 3.000

3.  Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.

Authors:  Ying Xiong; Hai-Ting Lu; Yongjian Li; Guang-Fu Yang; Chang-Guo Zhan
Journal:  Biophys J       Date:  2006-09-01       Impact factor: 4.033

4.  Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition.

Authors:  Bryan D Devan; Jonna L Bowker; Kara B Duffy; Ila S Bharati; Mariana Jimenez; Demetrio Sierra-Mercado; Christopher M Nelson; Edward L Spangler; Donald K Ingram
Journal:  Psychopharmacology (Berl)       Date:  2005-11-18       Impact factor: 4.530

Review 5.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

6.  Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study.

Authors:  Y S Shim; C-U Pae; K J Cho; S W Kim; J C Kim; J S Koh
Journal:  Int J Impot Res       Date:  2013-11-28       Impact factor: 2.896

7.  Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling.

Authors:  Eva Bollen; Daniela Puzzo; Kris Rutten; Lucia Privitera; Jochen De Vry; Tim Vanmierlo; Gunter Kenis; Agostino Palmeri; Rudi D'Hooge; Detlef Balschun; Harry M W Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Neuropsychopharmacology       Date:  2014-05-12       Impact factor: 7.853

8.  Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies.

Authors:  C B Brink; J D Clapton; B E Eagar; B H Harvey
Journal:  J Neural Transm (Vienna)       Date:  2007-09-07       Impact factor: 3.575

Review 9.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

10.  Pharmacokinetics of acute tryptophan depletion using a gelatin-based protein in male and female Wistar rats.

Authors:  L A W Jans; C K J Lieben; L T Smits; A Blokland
Journal:  Amino Acids       Date:  2008-08-06       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.